PHASE 1/1B, MULTICENTER, OPEN-LABEL, STUDY OF RMC-9805 IN PARTICIPANTS WITH ADVANCED KRASG12D-MUTANT SOLID TUMORS

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in
combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Inclusion Criteria:

- Pathologically documented, locally advanced or metastatic solid tumor with a KRAS
G12D-mutation

- Received and progressed or been intolerant to prior standard therapy (including
targeted therapy) appropriate for tumor type and stage

- ECOG performance status 0 or 1

- Adequate organ function

Exclusion Criteria:

- Primary central nervous system (CNS) tumors

- Known or suspected leptomeningeal or active brain metastases or spinal cord
compression

- Known or suspected impairment of gastrointestinal function that may prohibit ability
to swallow or absorb an oral medication

- Participant was previously treated with an investigational KRAS G12D inhibitor, pan-
or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy
(eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.